This page shows the publications co-authored by Zexian Zeng and Jingxin Fu.
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response. Nucleic Acids Res. 2021 Sep 17.
Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clin Cancer Res. 2021 Sep 15; 27(18):5049-5061.
In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target. Cell. 2021 Oct 14; 184(21):5357-5374.e22.
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 2021 Jun; 11(6):1524-1541.
Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biol. 2020 10 15; 21(1):263.
TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020 07 02; 48(W1):W509-W514.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.